|ClinicalTrials.gov Identifier: NCT01653834|
Recruitment Status : Completed
First Posted : July 31, 2012
Last Update Posted : August 12, 2014
|Condition or disease||Intervention/treatment||Phase|
|Glioblastoma||Biological: Harvesting and reinfusion of autologous lymphocytes||Not Applicable|
The patients blood will be collected (apheresis) before starting the patients planned standard of care radiation therapy and chemotherapy:
- An IV will be inserted into the vein in the patients arm.
- The blood will be sent to a machine that removes the lymphocytes and returns the rest to the patient.
- This procedure will last from 1 hour and 15 minutes to 4 hours.
- During this time the patient will also be treated with a blood thinner to prevent the blood from clotting in the machine.
- The lymphocytes will be counted and stored. If an insufficient number were collected, we will ask for another similar collection in about 1 week.
- After the patient has completed the full 6 weeks of radiation, all of the lymphocytes will be returned to the patient through a simple intravenous infusion. A larger intravenous access (i.e. midline) might be needed. Any cells that are not reinfused will be stored for 1 year and then discarded.
- Study bloods (10 ml) will be collected at the time of lymphocyte collection, prior lymphocyte reinfusion, and then every 2 weeks until week 20th. These blood samples will be stored and used for future analysis.
Blood counts are obtained weekly as part of standard care for patients with this kind of brain tumor. For the first 14 weeks after the lymphocyte reinfusion we will be doing some extra tests on the routinely collected blood to see how the effective the reinfused lymphocytes are in raising the patients lymphocyte counts. These results will be available to the patients treating physician.
At no time will this study interfere with the patients planned standard of care radiation and chemotherapy.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas|
|Study Start Date :||July 2012|
|Actual Primary Completion Date :||January 2014|
|Actual Study Completion Date :||March 2014|
Experimental: all pts with lymphocyte harvesting and reinfusion
pts will be treated with standard temozolmide and radiation, prior to treatment will have lymphocytes harvested (collected and stored) and at week 10 pts lymphocytes will be re-infused. Lymphocyctes will be checked weekly for 14weeks until week 20
Biological: Harvesting and reinfusion of autologous lymphocytes
collect lymphocytes prior to pts starting RT/chemo and put them back after pt completes RT
- the feasibility of lymphocyte harvesting and reinfusion [ Time Frame: 10 weeks ]this will be considered a feasible approach if 5 of the 10 patients to be accrued have an absolute lymphocyte count increase of 300 cells per mm3 at 4 weeks after reinfusion.
- the number of lymphocytes that can be harvested in this pt population [ Time Frame: 10 weeks ]the number of lymphocytes harvested per patient
- duration of lymphocyte rise following lymphocyte reinfusion [ Time Frame: 10 weeks ]how long will lymphocyte counts remain elevated after reinfusion
- changes in lymphocyte subtypes following collection and reinfusion [ Time Frame: 10 weeks ]changes in lymphocyte subtype between collection and reinfusion as a result of freezing for storage.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01653834
|United States, Maryland|
|Johns Hopkins University|
|Baltimore, Maryland, United States, 21287|